A Phase 2 interventional study of tucatinib and trastuzumab in Uterine Neoplasms, Uterine Cervical Neoplasms and Biliary Tract Neoplasms, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Active, not recruiting at 108 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Uterine Cervical Neoplasms by Pfizer — 3 open to participants now, 4 under way, none of them phase 3. Uterine Cervical Neoplasms · Pfizer.
Among the 17 studies in Uterine Cervical Neoplasms by Pfizer, this one is the 3rd largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2021, is one of 4 in phase 2, and was the 11th registered.
2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →3 of the 17 studies in Uterine Cervical Neoplasms by Pfizer are open now, in 8 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Puerto Rico
Ages 18+ · Women only
Seagen, a wholly owned subsidiary of Pfizer · Sites in United States, France, Korea, Republic of and 4 more countries
Ages 18+
Pfizer
Ages 18+
By country, each count listing its studies:
Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 7 · Phase 3 1 · Phase 4 2
First in 2004; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 217 is above the median of 100 across 1,739 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 122 across the 16 interventional studies, 0 across the 1 observational. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Seagen, a wholly owned subsidiary of Pfizer, one of the names counted as Pfizer. Under that name alone:
Seagen, a wholly owned subsidiary of Pfizer is the lead sponsor of 30 studies on the registry; 4 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 3 (27%) have results posted.
1 of the studies in Uterine Cervical Neoplasms by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04389632Seagen, a wholly owned subsidiary of PfizerA Study of Sigvotatug Vedotin in Advanced Solid Tumors | 2027-06-16 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Uterine Cervical Neoplasms by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable).
All participants will get both tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get a drug called fulvestrant.
The trial will also look at what side effects happen. A side effect is anything a drug does besides treating cancer.
There are multiple cohorts in this trial:
2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
This study's enrollment of 217 is above the median of 100 across 1,739 interventional studies indexed under Uterine Cervical Neoplasms.
Browse Uterine Cervical Neoplasms studies →Seagen, a wholly owned subsidiary of Pfizer is the lead sponsor of 30 studies on the registry; 4 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 3 (27%) have results posted.
First submitted before Seagen Inc. became part of Pfizer.
Compared within Uterine Cervical Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Uterine Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Disease demonstrating alterations (overexpression/amplification or HER2 activating mutations), as determined by local or central testing processed in a Clinical Laboratory Improvement Amendments (CLIA)- or International Organization for Standardization (ISO) accredited laboratory, according to one of the following:
Exclusion Criteria
There are additional inclusion and exclusion criteria. The study center will determine if criteria for participation are met.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tucatinib + trastuzumab (+ fulvestrant in hormone-receptor positive HER2-mutant breast cancer only)
Drug: tucatinib · Drug: trastuzumab · Drug: fulvestrant
300 mg orally twice daily
Also known as: TUKYSA, ARRY-380, ONT-380
Given into the vein (intravenously; IV). 8mg/kg IV on Cycle 1 Day 1, and 6mg/kg every 21 days starting on Cycle 2 Day 1
Also known as: Herceptin
Given into the muscle (intramuscular; IM) once every 4 weeks starting from Cycle 1 Day 1, plus one dose on Cycle 1 Day 15. Only administered to participants with hormone-receptor positive breast cancer.
Also known as: Faslodex
Confirmed Objective Response Rate (cORR) as Assessed by Investigator
Confirmed ORR was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v)1.1 as assessed by investigator and was considered as confirmed when subsequent response was at least 4 weeks after initial response. As per RECIST v1.1, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeter (mm). PR: at least a greater than or equal to (\>=)30 % decrease in the sum of diameters (SOD) of target lesions (longest for non-nodal target lesions and the short axes for nodal target lesions), taking as reference the baseline sum diameters. Disease progression (PD): at least \>=20% relative increase in SOD of target lesion taking as reference the smallest sum on study (including baseline sum if that is the smallest on study).
Time frame: From the first dose of study treatment until the first documented CR or PR on or before the first documented PD or new anti-cancer therapies or death, whichever occurred first (up to 28.3 months)
Confirmed Disease Control Rate (DCR) as Assessed by Investigator
DCR was defined as the percentage of participants with confirmed CR, PR, or stable disease (SD or non-CR/non-PD) according to RECIST v1.1 as assessed by investigator. As per RECIST v1.1, CR: disappearance of all target (T) lesions and non-target (NT) lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least \>=30 % decrease in the SOD of target lesions (longest for non-nodal target lesions and the short axes for nodal target lesions), taking as reference the baseline sum diameters. PD: at least \>=20% relative increase in SOD of target lesions taking as reference the smallest sum on study (including baseline sum if that is the smallest on study). SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD while on study and cannot have met criteria for PD previously.
Time frame: From the first dose study treatment until PD or death, whichever occurred first (approximately 52.7 months)
Duration of Response (DOR) as Assessed by Investigator
DOR: time from first documentation of confirmed CR/PR to first documentation of PD according to RECIST v1.1 or death from any cause, whichever occurred earlier. Per RECIST v1.1, CR: disappearance of all T/NT lesions(L). Any pathological lymph nodes (whether T/NT) must have reduction in short axis to \<10 mm. PR: at least \>=30 % decrease in SOD of TL, taking reference baseline sum diameters. PD: at least \>=20% relative increase in SOD of TL taking reference smallest sum on study. Participants who do not have PD \& were still on study at time of an analysis/ who have started new anticancer treatment/discontinue prior to documentation of PD were censored at date of last adequate response assessment documenting absence of PD. Participants who had PD/death occurred after two/more consecutive missing scheduled response assessments were censored at date of last adequate response assessment of CR, PR, SD,/non-CR/non-PD. Kaplan-Meier method was used for evaluation.
Time frame: From the first documented CR or PR until the first documentation of PD or death or censoring date, whichever occurred first (approximately 52.7 months)
Progression-Free Survival (PFS) as Assessed by Investigator
PFS was defined as time from the date of treatment initiation to date of PD as per RECIST v1.1 or death from any cause, whichever occurred first . As per RECIST v1.1, PD: least \>=20% relative increase in SOD of target lesions taking as reference the smallest sum on study (including baseline sum if that is smallest on study). Participants who do not have PD and were still on study at time of an analysis/ who have started new anticancer treatment/discontinue prior to documentation of PD were censored at date of last adequate response assessment documenting absence of PD. Participants who had PD or death occurred after two or more consecutive missing scheduled response assessments were censored at date of last adequate response assessment of CR, PR, SD,/non-CR/non-PD. Kaplan-Meier method was used for evaluation.
Time frame: From the first documented CR or PR until the first documentation of PD or death or censoring date, whichever occurred first (approximately 52.7 months)
Overall Survival (OS)
OS was defined as the time from treatment initiation to death due to any cause. For a participant who was not known to have died by the end of study follow-up, observation of OS was censored on the date the participant was last known to be alive (i.e., the date of last contact). Participants lacking data beyond the day of treatment initiation were censored on the date of treatment initiation (i.e., OS duration of 1 day). Kaplan-Meier method was used for evaluation.
Time frame: From date of start of study treatment until date of death or censoring date (approximately 52.7 months)
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An AE was any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment.
Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (approximately 52.7 months)
Number of Participants With Treatment Emergent Laboratory Test Abnormalities
Treatment-emergent laboratory abnormalities were defined as abnormalities that are new or worsened on or after receiving the first dose of study treatment up to 30 days after the last dose of study treatment. The following laboratory abnormalities were assessed: A-) Hematology: hemoglobin decreased, leukocytes decreased, lymphocytes decreased and increased, neutrophils decreased and platelets decreased; B-) Chemistry: alanine aminotransferase increased, albumin decreased, alkaline phosphatase increased, aspartate aminotransferase increased, calcium corrected for albumin decreased and increased, creatinine increased, glomerular filtration rate estimated decreased, glucose decreased, lactate dehydrogenase increased, magnesium increased and decreased, potassium increased and decreased, sodium increased and decreased and total bilirubin increased.
Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (approximately 52.7 months)
Number of Participants With Any Dose Modifications Due to AEs
Dose modification included dose hold, dose reduction, or discontinuation of drugs. Dose reductions or treatment interruption/discontinuation were made at the discretion of the investigator.
Time frame: From first dose of the study treatment (Day 1) up to the last dose of study treatment (approximately 52.7 months)
Number of Participants With TEAEs of Special Interest
An adverse event of special interest (AESI) were any serious or nonserious AE that were of scientific or medical concern as defined by the sponsor and specific to the program, for which ongoing monitoring and rapid communication to the sponsor were appropriate. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment (tucatinib, trastuzumab or fulvestrant). AESIs for this study were related to hepatoxicity.
Time frame: From first dose of the study treatment (Day 1) up to the last dose of study treatment (approximately 52.7 months)
Maximum Concentration (Cmax) of Tucatinib
Time frame: Cycle 3 Day 1: anytime within 1-4 hours post-dose
Trough Concentration (Ctrough) of Tucatinib
Time frame: Cycle 3 Day 1: Predose
Participants with locally-advanced (LA) unresectable or metastatic solid tumors driven by human epidermal growth factor receptor 2 (HER2) alterations, who were previously treated, were enrolled to receive tucatinib in combination with trastuzumab in this study. Participants with hormone-receptor positive breast cancer also received fulvestrant.
| Milestone | Tucatinib+Trastuzumab (Cohort 1) | Tucatinib+Trastuzumab (Cohort 2) | Tucatinib+Trastuzumab (Cohort 3) | Tucatinib+Trastuzumab (Cohort 4) | Tucatinib+Trastuzumab (Cohort 5) | Tucatinib+Trastuzumab (Cohort 6) | Tucatinib+Trastuzumab (Cohort 7) | Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8) | Tucatinib+Trastuzumab (Cohort 9) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 11 | 31 | 30 | 25 | 12 | 31 | 13 | 31 | 33 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 11 | 31 | 30 | 25 | 12 | 31 | 13 | 31 | 33 |
| Withdrew: Death | 9 | 22 | 22 | 17 | 6 | 21 | 10 | 11 | 25 |
| Withdrew: Withdrawal by subject | 0 | 3 | 4 | 0 | 1 | 2 | 0 | 1 | 2 |
| Withdrew: Ongoing | 2 | 6 | 4 | 8 | 5 | 8 | 3 | 19 | 6 |
Confirmed ORR was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v)1.1 as assessed by investigator and was considered as confirmed when subsequent response was at least 4 weeks after initial response. As per RECIST v1.1, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeter (mm). PR: at least a greater than or equal to (\>=)30 % decrease in the sum of diameters (SOD) of target lesions (longest for non-nodal target lesions and the short axes for nodal target lesions), taking as reference the baseline sum diameters. Disease progression (PD): at least \>=20% relative increase in SOD of target lesion taking as reference the smallest sum on study (including baseline sum if that is the smallest on study).
| Percentage of participants | Tucatinib+Trastuzumab (Cohort 1) | Tucatinib+Trastuzumab (Cohort 2) | Tucatinib+Trastuzumab (Cohort 3) | Tucatinib+Trastuzumab (Cohort 4) | Tucatinib+Trastuzumab (Cohort 5) | Tucatinib+Trastuzumab (Cohort 6) | Tucatinib+Trastuzumab (Cohort 7) | Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8) | Tucatinib+Trastuzumab (Cohort 9) |
|---|---|---|---|---|---|---|---|---|---|
| Confirmed Objective Response Rate (cORR) as Assessed by Investigator | 27.3 (7.9 to 56.4) | 13.3 (4.7 to 28.0) | 46.7 (30.8 to 63.0) | 8.0 (1.4 to 23.1) | 8.3 (0.4 to 33.9) | 22.6 (11.1 to 38.3) | 0 (0.0 to 20.6) | 41.9 (26.9 to 58.2) | 10.3 (2.9 to 24.6) |
DCR was defined as the percentage of participants with confirmed CR, PR, or stable disease (SD or non-CR/non-PD) according to RECIST v1.1 as assessed by investigator. As per RECIST v1.1, CR: disappearance of all target (T) lesions and non-target (NT) lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least \>=30 % decrease in the SOD of target lesions (longest for non-nodal target lesions and the short axes for nodal target lesions), taking as reference the baseline sum diameters. PD: at least \>=20% relative increase in SOD of target lesions taking as reference the smallest sum on study (including baseline sum if that is the smallest on study). SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD while on study and cannot have met criteria for PD previously.
Results for this outcome have not been posted.
DOR: time from first documentation of confirmed CR/PR to first documentation of PD according to RECIST v1.1 or death from any cause, whichever occurred earlier. Per RECIST v1.1, CR: disappearance of all T/NT lesions(L). Any pathological lymph nodes (whether T/NT) must have reduction in short axis to \<10 mm. PR: at least \>=30 % decrease in SOD of TL, taking reference baseline sum diameters. PD: at least \>=20% relative increase in SOD of TL taking reference smallest sum on study. Participants who do not have PD \& were still on study at time of an analysis/ who have started new anticancer treatment/discontinue prior to documentation of PD were censored at date of last adequate response assessment documenting absence of PD. Participants who had PD/death occurred after two/more consecutive missing scheduled response assessments were censored at date of last adequate response assessment of CR, PR, SD,/non-CR/non-PD. Kaplan-Meier method was used for evaluation.
Results for this outcome have not been posted.
PFS was defined as time from the date of treatment initiation to date of PD as per RECIST v1.1 or death from any cause, whichever occurred first . As per RECIST v1.1, PD: least \>=20% relative increase in SOD of target lesions taking as reference the smallest sum on study (including baseline sum if that is smallest on study). Participants who do not have PD and were still on study at time of an analysis/ who have started new anticancer treatment/discontinue prior to documentation of PD were censored at date of last adequate response assessment documenting absence of PD. Participants who had PD or death occurred after two or more consecutive missing scheduled response assessments were censored at date of last adequate response assessment of CR, PR, SD,/non-CR/non-PD. Kaplan-Meier method was used for evaluation.
Results for this outcome have not been posted.
OS was defined as the time from treatment initiation to death due to any cause. For a participant who was not known to have died by the end of study follow-up, observation of OS was censored on the date the participant was last known to be alive (i.e., the date of last contact). Participants lacking data beyond the day of treatment initiation were censored on the date of treatment initiation (i.e., OS duration of 1 day). Kaplan-Meier method was used for evaluation.
Results for this outcome have not been posted.
An AE was any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment.
Results for this outcome have not been posted.
Treatment-emergent laboratory abnormalities were defined as abnormalities that are new or worsened on or after receiving the first dose of study treatment up to 30 days after the last dose of study treatment. The following laboratory abnormalities were assessed: A-) Hematology: hemoglobin decreased, leukocytes decreased, lymphocytes decreased and increased, neutrophils decreased and platelets decreased; B-) Chemistry: alanine aminotransferase increased, albumin decreased, alkaline phosphatase increased, aspartate aminotransferase increased, calcium corrected for albumin decreased and increased, creatinine increased, glomerular filtration rate estimated decreased, glucose decreased, lactate dehydrogenase increased, magnesium increased and decreased, potassium increased and decreased, sodium increased and decreased and total bilirubin increased.
Results for this outcome have not been posted.
Dose modification included dose hold, dose reduction, or discontinuation of drugs. Dose reductions or treatment interruption/discontinuation were made at the discretion of the investigator.
Results for this outcome have not been posted.
An adverse event of special interest (AESI) were any serious or nonserious AE that were of scientific or medical concern as defined by the sponsor and specific to the program, for which ongoing monitoring and rapid communication to the sponsor were appropriate. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment (tucatinib, trastuzumab or fulvestrant). AESIs for this study were related to hepatoxicity.
Results for this outcome have not been posted.
| Nanogram per milliliter | Tucatinib+Trastuzumab (Cohort 1) | Tucatinib+Trastuzumab (Cohort 2) | Tucatinib+Trastuzumab (Cohort 3) | Tucatinib+Trastuzumab (Cohort 4) | Tucatinib+Trastuzumab (Cohort 5) | Tucatinib+Trastuzumab (Cohort 6) | Tucatinib+Trastuzumab (Cohort 7) | Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8) | Tucatinib+Trastuzumab (Cohort 9) |
|---|---|---|---|---|---|---|---|---|---|
| Maximum Concentration (Cmax) of Tucatinib | 488.2 ± 104.9 | 483.1 ± 53.5 | 319.2 ± 116.2 | 275.9 ± 122.8 | 437.2 ± 60.0 | 330.4 ± 164.2 | 207.7 ± 344.6 | 393.2 ± 255.6 | 242.9 ± 155.1 |
| Nanogram per milliliter | Tucatinib+Trastuzumab (Cohort 1) | Tucatinib+Trastuzumab (Cohort 2) | Tucatinib+Trastuzumab (Cohort 3) | Tucatinib+Trastuzumab (Cohort 4) | Tucatinib+Trastuzumab (Cohort 5) | Tucatinib+Trastuzumab (Cohort 6) | Tucatinib+Trastuzumab (Cohort 7) | Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8) | Tucatinib+Trastuzumab (Cohort 9) |
|---|---|---|---|---|---|---|---|---|---|
| Trough Concentration (Ctrough) of Tucatinib | 196.6 ± 100.1 | 99.9 ± 482.9 | 145.7 ± 383.0 | 105.1 ± 355.1 | 46.5 ± 3312.4 | 115.4 ± 328.3 | 267.4 ± 165.2 | 126.9 ± 234.5 | 142.3 ± 184.1 |
Collected over From first dose of the study treatment (Day 1) maximum up to 30 days after the last dose of study treatment death date, or data cut-off date, whichever was earlier (maximum up to 28.8 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tucatinib+Trastuzumab (Cohort 1) | 9/11 (81.8%) | 5/11 (45.5%) | 10/11 (90.9%) |
| Tucatinib+Trastuzumab (Cohort 2) | 22/31 (71%) | 11/31 (35.5%) | 30/31 (96.8%) |
| Tucatinib+Trastuzumab (Cohort 3) | 22/30 (73.3%) | 13/30 (43.3%) | 29/30 (96.7%) |
| Tucatinib+Trastuzumab (Cohort 4) | 17/25 (68%) | 9/25 (36%) | 23/25 (92%) |
| Tucatinib+Trastuzumab (Cohort 5) | 6/12 (50%) | 2/12 (16.7%) | 12/12 (100%) |
| Tucatinib+Trastuzumab (Cohort 6) | 21/31 (67.7%) | 9/31 (29%) | 29/31 (93.5%) |
| Tucatinib+Trastuzumab (Cohort 7) | 10/13 (76.9%) | 7/13 (53.8%) | 13/13 (100%) |
| Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8) | 11/31 (35.5%) | 8/31 (25.8%) | 31/31 (100%) |
| Tucatinib+Trastuzumab (Cohort 9) | 25/33 (75.8%) | 14/33 (42.4%) | 30/33 (90.9%) |
| Event | Tucatinib+Trastuzumab (Cohort 1) | Tucatinib+Trastuzumab (Cohort 2) | Tucatinib+Trastuzumab (Cohort 3) | Tucatinib+Trastuzumab (Cohort 4) | Tucatinib+Trastuzumab (Cohort 5) | Tucatinib+Trastuzumab (Cohort 6) | Tucatinib+Trastuzumab (Cohort 7) | Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8) | Tucatinib+Trastuzumab (Cohort 9) |
|---|---|---|---|---|---|---|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 0/11 | 1/31 | 1/30 | 3/25 | 0/12 | 0/31 | 0/13 | 1/31 | 2/33 |
| Abdominal painGastrointestinal disorders | 1/11 | 0/31 | 0/30 | 0/25 | 0/12 | 1/31 | 1/13 | 0/31 | 2/33 |
| ConstipationGastrointestinal disorders | 1/11 | 0/31 | 0/30 | 0/25 | 0/12 | 0/31 | 0/13 | 0/31 | 0/33 |
| EnteritisGastrointestinal disorders | 1/11 | 0/31 | 0/30 | 0/25 | 0/12 | 0/31 | 0/13 | 0/31 | 0/33 |
| Intestinal obstructionGastrointestinal disorders | 1/11 | 0/31 | 0/30 | 1/25 | 0/12 | 1/31 | 0/13 | 0/31 | 0/33 |
| Small intestinal obstructionGastrointestinal disorders | 1/11 | 1/31 | 0/30 | 0/25 | 0/12 | 0/31 | 0/13 | 0/31 | 0/33 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/11 | 0/31 | 0/30 | 0/25 | 0/12 | 0/31 | 0/13 | 0/31 | 0/33 |
| Laryngeal haemorrhageRespiratory, thoracic and mediastinal disorders | 1/11 | 0/31 | 0/30 | 0/25 | 0/12 | 0/31 | 0/13 | 0/31 | 0/33 |
| AnaemiaBlood and lymphatic system disorders | 0/11 | 0/31 | 0/30 | 0/25 | 1/12 | 0/31 | 0/13 | 0/31 | 0/33 |
| Atrial flutterCardiac disorders | 0/11 | 0/31 | 0/30 | 0/25 | 1/12 | 0/31 | 0/13 | 0/31 | 0/33 |
| Event | Tucatinib+Trastuzumab (Cohort 1) | Tucatinib+Trastuzumab (Cohort 2) | Tucatinib+Trastuzumab (Cohort 3) | Tucatinib+Trastuzumab (Cohort 4) | Tucatinib+Trastuzumab (Cohort 5) | Tucatinib+Trastuzumab (Cohort 6) | Tucatinib+Trastuzumab (Cohort 7) | Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8) | Tucatinib+Trastuzumab (Cohort 9) |
|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 7/11 | 16/31 | 12/30 | 13/25 | 9/12 | 13/31 | 9/13 | 19/31 | 12/33 |
| NauseaGastrointestinal disorders | 6/11 | 13/31 | 6/30 | 6/25 | 3/12 | 7/31 | 4/13 | 11/31 | 9/33 |
| VomitingGastrointestinal disorders | 5/11 | 12/31 | 4/30 | 2/25 | 2/12 | 7/31 | 4/13 | 9/31 | 10/33 |
| Blood creatinine increasedInvestigations | 5/11 | 7/31 | 8/30 | 5/25 | 2/12 | 9/31 | 3/13 | 3/31 | 7/33 |
| PyrexiaGeneral disorders | 3/11 | 4/31 | 13/30 | 4/25 | 1/12 | 13/31 | 1/13 | 6/31 | 10/33 |
| ChillsGeneral disorders | 4/11 | 5/31 | 7/30 | 7/25 | 2/12 | 11/31 | 4/13 | 6/31 | 13/33 |
| FatigueGeneral disorders | 2/11 | 12/31 | 4/30 | 4/25 | 2/12 | 5/31 | 5/13 | 6/31 | 7/33 |
| Infusion related reactionInjury, poisoning and procedural complications | 3/11 | 6/31 | 8/30 | 8/25 | 4/12 | 12/31 | 3/13 | 8/31 | 12/33 |
| Alanine aminotransferase increasedInvestigations | 4/11 | 4/31 | 8/30 | 5/25 | 3/12 | 7/31 | 3/13 | 4/31 | 8/33 |
| Weight decreasedInvestigations | 4/11 | 3/31 | 1/30 | 5/25 | 1/12 | 3/31 | 1/13 | 2/31 | 1/33 |
The Full Analysis Set (FAS) included all participants who were enrolled in the study and received any amount of study treatment.
| Age, Continuous(Years) | Tucatinib+Trastuzumab (Cohort 1) | Tucatinib+Trastuzumab (Cohort 2) | Tucatinib+Trastuzumab (Cohort 3) | Tucatinib+Trastuzumab (Cohort 4) | Tucatinib+Trastuzumab (Cohort 5) | Tucatinib+Trastuzumab (Cohort 6) | Tucatinib+Trastuzumab (Cohort 7) | Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8) | Tucatinib+Trastuzumab (Cohort 9) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 53.6 ± 15.3 | 67.6 ± 7.4 | 66.4 ± 10.1 | 67.5 ± 11.6 | 69.7 ± 11.1 | 62.7 ± 10.7 | 71.3 ± 9.5 | 61.3 ± 10.3 | 63.8 ± 10.5 | 64.9 ± 11.0 |
| Sex: Female, Male(Participants) | Tucatinib+Trastuzumab (Cohort 1) | Tucatinib+Trastuzumab (Cohort 2) | Tucatinib+Trastuzumab (Cohort 3) | Tucatinib+Trastuzumab (Cohort 4) | Tucatinib+Trastuzumab (Cohort 5) | Tucatinib+Trastuzumab (Cohort 6) | Tucatinib+Trastuzumab (Cohort 7) | Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8) | Tucatinib+Trastuzumab (Cohort 9) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 11 | 31 | 15 | 6 | 4 | 20 | 6 | 31 | 16 | 140 |
| Male | 0 | 0 | 15 | 19 | 8 | 11 | 7 | 0 | 17 | 77 |
| Ethnicity (NIH/OMB)(Participants) | Tucatinib+Trastuzumab (Cohort 1) | Tucatinib+Trastuzumab (Cohort 2) | Tucatinib+Trastuzumab (Cohort 3) | Tucatinib+Trastuzumab (Cohort 4) | Tucatinib+Trastuzumab (Cohort 5) | Tucatinib+Trastuzumab (Cohort 6) | Tucatinib+Trastuzumab (Cohort 7) | Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8) | Tucatinib+Trastuzumab (Cohort 9) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 | 2 | 1 | 2 | 0 | 2 | 1 | 10 |
| Not Hispanic or Latino | 11 | 29 | 26 | 17 | 8 | 25 | 9 | 24 | 30 | 179 |
| Unknown or Not Reported | 0 | 1 | 3 | 6 | 3 | 4 | 4 | 5 | 2 | 28 |
| Race (NIH/OMB)(Participants) | Tucatinib+Trastuzumab (Cohort 1) | Tucatinib+Trastuzumab (Cohort 2) | Tucatinib+Trastuzumab (Cohort 3) | Tucatinib+Trastuzumab (Cohort 4) | Tucatinib+Trastuzumab (Cohort 5) | Tucatinib+Trastuzumab (Cohort 6) | Tucatinib+Trastuzumab (Cohort 7) | Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8) | Tucatinib+Trastuzumab (Cohort 9) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 6 | 9 | 23 | 5 | 3 | 20 | 1 | 11 | 23 | 101 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 4 | 1 | 2 | 0 | 0 | 1 | 1 | 0 | 10 |
| White | 4 | 18 | 3 | 12 | 6 | 5 | 7 | 15 | 8 | 78 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 3 | 6 | 3 | 6 | 4 | 4 | 2 | 28 |
Showing the first 100 of 108 sites across 8 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2021 to primary completion in Nov 2023, 33 months.
Results were first posted in Nov 2024, 1 year after primary completion.
Of 50 industry-sponsored phase 2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 46. This study's 33 months is close to that.
Counting every sponsor, half of 204 studies reached it within 42 months; a quarter within 29 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tucatinib
Seagen, a wholly owned subsidiary of Pfizer →